(2021). One Health drivers of antibacterial resistance: Quantifying the relative impacts of human, animal and environmental use and transmission. One Health, 12, [100220].

with a disproportionate burden on lower-and middle-income countries (LMICs). It is not understood how ‘One Health ’ , where human health is co-dependent on animal health and the environment, might impact the burden of ABR in LMICs. Thailand ’ s 2017 “ National Strategic Plan on Antimicrobial Resistance ” (NSP-AMR) aims to reduce AMR morbidity by 50% through 20% reductions in human and 30% in animal antibacterial use (ABU). There is a need to understand the implications of such a plan within a One Health perspective. Methods: A model of ABU, gut colonisation with extended-spectrum beta-lactamase (ESBL)-producing bacteria and transmission was calibrated using estimates of the prevalence of ESBL-producing bacteria in Thailand. This model was used to project the reduction in human ABR over 20 years (2020 – 2040) for each One Health driver, including individual transmission rates between humans, animals and the environment, and to estimate the long-term impact of the NSP-AMR intervention. Results: The model predicts that human ABU was the most important factor in reducing the colonisation of humans with resistant bacteria (maximum 65.7 – 99.7% reduction). The NSP-AMR is projected to reduce human colonisation by 6.0 – 18.8%, with more ambitious targets (30% reductions in human ABU) increasing this to 8.5 – 24.9%. Conclusions: Our model provides a simple framework to explain the mechanisms underpinning ABR, suggesting that future interventions targeting the simultaneous reduction of transmission and ABU would help to control ABR more effectively in Thailand.